The effects of extracorporeal blood purification (oXiris®) in patients with cardiogenic shock who require venoarterial extracorporeal membrane oxygenation (VA-ECMO) (CLEAN ECMO): a prospective, open-label, randomized controlled pilot study
Authors' conclusion
In this pilot study conducted on CS patients requiring VA-ECMO, oXiris treatment did not significantly reduce endotoxin levels or improve patient centered clinical outcomes.
Study context
- Population
- Patients with cardiogenic shock undergoing VA-ECMO
- Participants
- 40 patients
- Comparison
- oXiris for 24 h vs usual care
- oXirisn = 20
- Usual caren = 20reference
- Primary endpoint
- Endotoxin levels
- Follow-up
- 48 h
Methodological detailsprospective, single-centre, open-label, pilot
- Prospective
- Single-centre
- Open-label
- Pilot
Primary result
As reported in the abstract
oXiris
0.5
median · IQR 0.4–1.0
Usual care
0.4
median · IQR 0.2–0.5
P = 0.097
Secondary outcomes
IL-6 (oXiris, change from baseline)
- Significant reduction from baseline to 24 h
- P = 0.020
- Significant reduction from baseline to 7 days
- P = 0.003
- Significant temporal reductions in GDF-15 and IL-6 in the oXiris group
Vasoactive-inotropic score (oXiris, change from baseline)
- Change baseline to 48 h
- −13.63, 95% CI: −20.90 - −6.34, P < 0.001
- Change baseline to 7 days
- −12.19, 95% CI: −21.0 - −3.31, P = 0.007
- Intergroup differences insignificant
ECMO weaning success, duration of ECMO support, mortality
- Similar between the groups
Original publication
The effects of extracorporeal blood purification (oXiris®) in patients with cardiogenic shock who require VA-ECMO (CLEAN ECMO): a prospective, open-label, randomized controlled pilot study. Crit Care. Published 20 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →